‘Marker-of-self’ functionalization of nanoscale particles through a top-down cellular membrane coating approach

Hu, Canbin; Fang, Ronnie H.; Luk, Brian T.; Chen, Kevin N H; Carpenter, Cody W.; Gao, Weiwei; Zhang, Kang; Zhang, Liangfang

doi:10.1039/c3nr00015j

Cited by 257 publications

(199 citation statements)

References 20 publications

Supporting

Mentioning

196

Contrasting

Order By: Relevance

“…[158] This transmembrane protein binds to signal regulatory protein alpha expressed by macrophages and myeloid cells, activating a sign known as "do not eat me" and suppressing the phagocytic processes. [159] As a consequence, surface modification of PLGA nanoparticles with CD47 market, considered as a "stealth or inert artificial structure," is indeed one of the most promising strategies to escape phagocyte uptake and consequently, early PLGA-based DDSs clearance. [160] Discher et al proved the successful attachment of CD47 "self" peptides to the surface of nanoparticles and the consequent increase in the circulation lifetime of the nanosystem, due to a delay in the phagocytic clearance by liver and spleen.…”

Section: Functionalized Poly(lactic-co-glycolic) Acid-based Drug Delimentioning

confidence: 99%

“…Reproduced with permission. [159] Ligand-receptor interaction Lectin Paclitaxel Functionalized paclitaxel-loaded PLGA nanoparticles presented a higher cellular uptake and a stronger cytotoxic effect than the nonfunctionalized ones.…”

Section: Scaffoldsmentioning

confidence: 99%

“…[162] CD47 role was demonstrated by the same research group, where it was found significant statistical differences, of around 20%, for the macrophage uptake between RBC-NPs and CD47-Blocked RBC-NPs (Figure 6). [159] An active targeted therapy has been an increasingly appealing strategy to enhance the efficiency of therapies, achieved through the attachment of specific ligands to PLGA-based DDSs surface (Figure 4b). This type of therapy allows the targeting of particles to a specific cell type by molecular recognition and thus, it can be modulated depending on the type of ligands.…”

Section: Functionalized Poly(lactic-co-glycolic) Acid-based Drug Delimentioning

confidence: 99%

See 2 more Smart Citations

Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications

Martins

Sousa

Araújo

et al. 2017

Adv Healthcare Materials

189

125

View full text Add to dashboard Cite

Poly(lactic‐co‐glycolic) acid (PLGA) is one of the most versatile biomedical polymers, already approved by regulatory authorities to be used in human research and clinics. Due to its valuable characteristics, PLGA can be tailored to acquire desirable features for control bioactive payload or scaffold matrix. Moreover, its chemical modification with other polymers or bioconjugation with molecules may render PLGA with functional properties that make it the Holy Grail among the synthetic polymers to be applied in the biomedical field. In this review, the physical–chemical properties of PLGA, its synthesis, degradation, and conjugation with other polymers or molecules are revised in detail, as well as its applications in drug delivery and regeneration fields. A particular focus is given to successful examples of products already on the market or at the late stages of trials, reinforcing the potential of this polymer in the biomedical field.

show abstract

Section: Functionalized Poly(lactic-co-glycolic) Acid-based Drug Delimentioning

confidence: 99%

Section: Scaffoldsmentioning

confidence: 99%

Section: Functionalized Poly(lactic-co-glycolic) Acid-based Drug Delimentioning

confidence: 99%

See 1 more Smart Citation

Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications

Martins

Sousa

Araújo

et al. 2017

Adv Healthcare Materials

189

125

View full text Add to dashboard Cite

show abstract

“…In these studies, CD47 is functionalized on nanoparticles in the exact conformation and density at which it is expressed on the surface of RBCs. 79 Vesicle-covered nanoparticles showed inhibition of macrophage phagocytosis and increased in vivo circulation time compared with polyethyleneglycol-covered nanoparticles showing significant particle retention in the blood at 72 h. 77,79 Anti-CD47 antibody partially blocked the effects of the vesicle coating. RBC membrane vesicles were also used to coat gold nanoparticles, which are often used both as imaging agents and drug carriers.…”

Section: Examples Of Cd47-modified Biomaterials Cd47-modified Therapementioning

confidence: 99%

“…Hu et al [77][78][79] created (RBC) membrane-derived vesicles as a biomimetic coating for poly lactic co-glycolic nanoparticles. In these studies, CD47 is functionalized on nanoparticles in the exact conformation and density at which it is expressed on the surface of RBCs.…”

Section: Examples Of Cd47-modified Biomaterials Cd47-modified Therapementioning

confidence: 99%

The use of CD47-modified biomaterials to mitigate the immune response

Tengood

Levy

Stachelek

2016

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Addressing the aberrant interactions between immune cells and biomaterials represents an unmet need in biomaterial research. Although progress has been made in the development of bioinert coatings, identifying and targeting relevant cellular and molecular pathways can provide additional therapeutic strategies to address this major healthcare concern. To that end, we describe the immune inhibitory motif, receptor-ligand pairing of signal regulatory protein alpha and its cognate ligand CD47 as a potential signaling pathway to enhance biocompatibility. The goals of this article are to detail the known roles of CD47-signal regulatory protein alpha signal transduction pathway and to describe how immobilized CD47 can be used to mitigate the immune response to biomaterials. Current applications of CD47-modified biomaterials will also be discussed herein.

show abstract

Biomimetic Nanoparticle Vaccines for Cancer Therapy

et al. 2018

Self Cite

View full text Add to dashboard Cite

It is currently understood that, in order for a tumor to successfully grow, it must evolve means of evading immune surveillance. In the past several decades, researchers have leveraged increases in our knowledge of tumor immunology to develop therapies capable of augmenting endogenous immunity and eliciting strong antitumor responses. In particular, the goal of anticancer vaccination is to train the immune system to properly utilize its own resources in the fight against cancer. Although attractive in principle, there are currently only limited examples of anticancer vaccines that have been successfully translated to the clinic. Recently, there has been a significant push towards the use of nanotechnology for designing vaccine candidates that exhibit enhanced potency and specificity. In this progress report, we discuss recent developments in the field of anticancer nanovaccines. By taking advantage of the flexibility offered by nanomedicine to purposefully program immune responses, this new generation of vaccines has the potential to address many of the hurdles facing traditional platforms. A specific emphasis is placed on the emergence of cell membrane-coated nanoparticles, a novel biomimetic platform that can be used to generate personalized nanovaccines that elicit strong, multi-antigenic antitumor responses.

show abstract

‘Marker-of-self’ functionalization of nanoscale particles through a top-down cellular membrane coating approach

Cited by 257 publications

References 20 publications

Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications

Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications

The use of CD47-modified biomaterials to mitigate the immune response

Biomimetic Nanoparticle Vaccines for Cancer Therapy

Contact Info

Product

Resources

About